Pinometostat (EPZ5676)

Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.

Pinometostat (EPZ5676) Chemical Structure

Pinometostat (EPZ5676) Chemical Structure

CAS: 1380288-87-8

Selleck's Pinometostat (EPZ5676) has been cited by 48 publications

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Products often used together with Pinometostat (EPZ5676)

Bay K 8644


Pinometostat and Bay K 8644, among other factors, combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

Hergenreder E, et al. Biorxiv (2022): 2022-06.

GSK2879552 2HCl


Pinometostat and GSK2879552, among other factors, combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

Hergenreder E, et al. Biorxiv (2022): 2022-06.

NMDA (N-Methyl-D-aspartic acid)


Pinometostat and NMDA, among other factors, combine to create a cocktail that promotes the maturation of neurons in 3D cortical organoids.

Hergenreder E, et al. Biorxiv (2022): 2022-06.

Sorafenib


Pinometostat treatment enhances Sorafenib's efficacy in both MLL-r and non-MLL-r leukemic cells by affecting the DOT1L-dependent regulation of RAF1 and BRAF.

Lonetti A, et al. Cancers (Basel). 2020 Jul; 12(7): 1972.

Trametinib (GSK1120212)


Pinometostat and Trametinib combinatorial treatment boosts the inhibitory effect on cell lines sensitive and resistant to DOT1L inhibition.

Raimondi A, et al. Mol Cancer Ther (2015) 14 (12_Supplement_2): B82.

Pinometostat (EPZ5676) Related Products

Choose Selective Histone Methyltransferase Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4-11 Function assay 4 days Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as reduction of H3K79me2 level after 4 days by ELISA method 25406853
MOLM13 Proliferation assay Antiproliferative activity against human MOLM13 cells containing MLL-AF9, EC50=4 nM 23879463
MV4-11 Proliferation assay Antiproliferative activity against human MV4-11 cells containing MLL-AF4, EC50=4 nM 23879463
THP1 Proliferation assay Antiproliferative activity against human THP1 cells containing MLL-AF9, EC50=4 nM 23879463
HeLa Function assay 72 hrs Inhibition of DOT1L in human HeLa cells assessed as reduction in H3K79me2 level after 72 hrs by ELISA, IC50 = 0.007 μM. 28337327
MV4-11 Antiproliferative assay 6 hrs Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 treated for 6 hrs measured after 8 days by Celltiter-Glo reagent based assay, IC50 = 0.015 μM. 28337327
MOLM13 Function assay 72 hrs Inhibition of DOT1L in human MOLM13 cells assessed as suppression of HoxA9 gene after 72 hrs by luciferase reporter gene assay, IC50 = 0.052 μM. 28337327
Click to View More Cell Line Experimental Data

Biological Activity

Description Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.
Targets
DOT1L [1]
(Cell-free assay)
80 pM(Ki)
In vitro
In vitro

EPZ-5676 reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. EPZ-5676 treatment results in concentration- and time-dependent reduction of H3K79 methylation without effect on the methylation status of other histone sites, which leads to inhibition of key MLL target genes and selective, apoptotic cell killing in MLL-rearranged leukemia cells. EPZ-5676 inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM.

Cell Research Cell lines MV4-11 cells
Concentrations 0.003 uM
Incubation Time 4 days
Method

Cells were treated with various concentrations of EPZ-5676.

Experimental Result Images Methods Biomarkers Images PMID
Western blot p-p65 / p65 / NFATc1 CDK6 / BCL11A / Bcl-2 / RUNX1 / MEF2C / H3K79me3 / H4 29348610
Immunofluorescence NFATc1 29348610
In Vivo
In vivo

EPZ-5676 continuously intravenous infusion for 21 days to xenograft model of MLL-rearranged leukemia, leads to dose-dependent anti-tumor activity. At the highest dose of 70.5 mg/kg/day, complete tumor regressions are achieved with no regrowth for up to 32 days after the cessation of treatment. No significant weight loss or obvious toxicity is observed in rats treated with EPZ-5676 during efficacy study.

Animal Research Animal Models NCr nu/nu mouse
Dosages 20 mg/kg
Administration i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02141828 Completed
Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Leukemias
Epizyme Inc.|Celgene Corporation|Ipsen
May 2014 Phase 1
NCT01684150 Completed
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders
Epizyme Inc.|Celgene|Ipsen
September 2012 Phase 1

Chemical Information & Solubility

Molecular Weight 562.71 Formula

C30H42N8O3

CAS No. 1380288-87-8 SDF Download Pinometostat (EPZ5676) SDF
Smiles CC(C)N(CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (177.71 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 25 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is the vehicle 30% PEG400/0.5% Tween80/5% propylene glycol recommended for in vivo use?

Answer:
S7062 EPZ-5676 in 30% PEG400/0.5% Tween80/5% propylene glycol at 30 mg/ml is a suspension. For injection, 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml is suitable.

Tags: buy Pinometostat|Pinometostat ic50|Pinometostat price|Pinometostat cost|Pinometostat solubility dmso|Pinometostat purchase|Pinometostat manufacturer|Pinometostat research buy|Pinometostat order|Pinometostat mouse|Pinometostat chemical structure|Pinometostat mw|Pinometostat molecular weight|Pinometostat datasheet|Pinometostat supplier|Pinometostat in vitro|Pinometostat cell line|Pinometostat concentration|Pinometostat nmr|Pinometostat in vivo|Pinometostat clinical trial|Pinometostat inhibitor|Pinometostat Epigenetics inhibitor